Focusing on pathways that are active in tumour proliferation, In3Bio has created a robust and diversified pipeline of novel therapeutics addressing multiple indications. ​

Pipeline

Our pipeline contains both single and bi-specific molecules targeting different pathways active in solid tumours. Our width and strength enable us to create potential solutions for different cancer indications

IN01
IN02
IN03
IN04
IN05

IN01 has been approved for a Phase I/II Colorectal (mutated) trial that can start in Q1 2022